Clinical Trial Update: Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial update of a fixed-dose combination (fimasartan/amlodipine/rosuvastatin) in patients with essential hypertension and dyslipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Essential Hypertension

Drugs mentioned

• Fimasartan/Amlodipine/Rosuvastatin

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Essential Hypertension, Dyslipidemia | Phase 3 | Status: COMPLETED